Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus NAPRELAN.
COXANTO vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
1 g intravenous every 6 hours.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category C
Category C
NSAID
NSAID